Xiamen University

抬起头仰望浩瀚星空 侧耳倾听 梦想的回声在耳畔响起 来往无数次的孤独小径上 陪伴你的不只有你的影子 还有小夏为你送上的鼓励 又是一年考研季 这一次换上小夏为你 专门打造的壁纸吧 让我们一起乘风破浪 四季更迭  多少个满怀期待的夜晚 你在案前沉思  跌跌撞撞走到今天 如今这段路程已经即将迎来终点 坚韧的你 已然经历涅槃 剩下的时光里 请以更坚定的步伐 迈向明天吧 或许你也曾遭遇挫折 或许失落的影子时常徘徊 但愿在碰上人生难关的时候 你会是它最棒的对手 有的事一旦决定了 就只顾风雨兼程 狂风吹不倒脆弱的蒲公英 只会播下无数希望的种子 每一个看似失望的瞬间 总能在喘息后遇到新的希望 一次次的磨练 都是成功的试炼 看似平淡不起眼的一天 都是在为未来的欢笑积蓄力量 伏案耕耘的同时不忘仰望星空 才能更清楚自己眼前的道路 我们都是青春年华 可以经历更大的风浪 黎明前的微凉 也会被你的笑容温暖 让我们期冀年末的绚烂 我们 一“研”为定    来年厦园见！ 考研加油！ ▲10月，____刷爆了厦大人的朋友圈🤩 ▲有图有方法！一键查收厦大学霸秘笈！ ▲无兄弟，不篮球！厦大赛场热血开赛！ 文：徐启玉 图：苏耀坤、莫凡、邓钧、郝泽、龚君、钟勋、林宇阳 图片设计：赵景涵、游惠婷、甘宇煊、王佳如 排版：曾文希  责编：张火火 厦门大学党委宣传部出品 快给正朝着梦想努力的自己点个 赞 和 在看 ！

脂肪组织在机体的代谢与能量平衡中扮演重要的角色。棕色脂肪组织（Brown adipose tissue，BAT）富含大量线粒体，可以利用葡萄糖和脂质产生热量，对于哺乳动物的体温维持和能量消耗至关重要。具有较高棕色脂肪产热活性的小鼠表现出更高的能量消耗，从而具有抵抗体重增加的能力。在婴儿和成人中都存在具有产热功能的棕色脂肪组织。人类棕色脂肪组织的活性增加与体重减轻显著相关。因此，促进棕色脂肪组织的发育和功能可能成为对抗肥胖及其相关代谢紊乱的有效策略。 SOX4是转录因子SRY-related high mobility group box（Sox）家族的一员，可以结合在目标DNA序列上，重塑染色质结构促进转录，在调节细胞干性、细胞分化，神经系统、内分泌胰岛和心脏的发育，以及癌症发生中发挥关键作用。本研究发现急剧冷刺激能够上调BAT组织及基质血管组分细胞（SVFs）中的SOX4表达。棕色脂肪祖细胞敲除SOX4的小鼠BAT表现出比野生型小鼠更加明显的白化现象，小鼠在急性冷刺激下的体温下降更快。 相对于野生型的正常小鼠，遗传性肥胖小鼠（ob/ob小鼠）、高脂诱导的肥胖小鼠以及年老的小鼠，棕色脂肪也会出现白化现象，相应的是BAT的SOX4表达也显著下调，这些结果提示SOX4对于棕色脂肪发育和功能维持具有重要作用。EBF2是决定棕色脂肪细胞命运的重要转录因子，但其上游调控因子尚不明确。该研究通过RNA-Seq和ChIP-Seq等实验发现，SOX4可以通过调控Ebf2转录，进一步调控BAT选择性基因以及产热基因的表达。分析不同阶段小鼠胚胎BAT单细胞转录组的数据，结果显示SOX4与EBF2表达在小鼠BAT早期发育中存在空间一致性，而且SOX4的表达高峰略早于EBF2。 这些结果表明SOX4通过调控EBF2的表达影响棕色脂肪的早期发育。进一步的研究发现，冷刺激可以通过cAMP-PKA信号通路促进SOX4的磷酸化，从而促进其进入细胞核并增强对Ebf2的转录。此外，SOX4 与 EBF2 协同作用，激活控制产热基因表达的转录程序（图1）。通过腺相关病毒（AAV）介导SOX4在棕色脂肪细胞过表达可以增加小鼠BAT的产热基因表达，使小鼠抵抗高脂饮食诱导的肥胖。 图1. SOX4与EBF2协同作用增强Ebf2和产热基因的表达 近日，该研究以题为“SOX4 facilitates brown fat development and maintenance through EBF2-mediated thermogenic gene program in mice” 在线发表于Cell Death & Differentiation。该研究发现了SOX4通过EBF2调控棕色脂肪发育和功能的分子机制，此过程受cAMP-PKA信号调控，揭示了SOX4在棕色脂肪细胞发育和肥胖发生中的生理作用，可能为预防和治疗肥胖和相关代谢疾病提供新的思路。 生命科学学院王帅、何婷和厦门大学医学院罗芽为该论文共同第一作者，厦门大学生命科学学院李博安教授、郭慧玲副教授，厦门大学附属第一医院李卫华教授和厦门大学医学院李奇渊教授为该论文的共同通讯作者。该研究得到国家自然科学基金、国家重点研发计划、专项博士后科学基金的资助。 论文链接： https://doi.org/10.1038/s41418-024-01397-0 原文链接： https://life.xmu.edu.cn/info/1045/28711.htm 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- MitrAssist Lifesciences, a leader in innovative cardiovascular medical devices, today unveiled the initial clinical results of its groundbreaking new product, SIKELIA™, during the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C. The early findings demonstrate promising potential in improving outcomes for patients suffering from severe symptomatic aortic stenosis. SIKELIA transthoracic heart valve (THV) is designed for transcatheter aortic valve implantation (TAVI) procedure. It features a unique polymer leaflet design which allows enhanced durability and reduced thrombogenicity and calcification while lowering production costs. SIKELIA THV is also fully retrievable at 100% frame expansion allowing reposition in case of misplacement. The clinical trial results, involving 12 patients from 4 centers, with a maximum follow up of 27 months, revealed favorable safety and performance 1-year outcomes. A significant improvement in hemodynamic performance was demonstrated by reduced mean pressure gradient and increased effective orifice area. The functional status as assessed by NYHA class, 6-minute walk test and KCCQ score was improved significantly in all measures. In addition, at 1 year follow-up, normal leaflet mobility without hypoattenuated leaflet thickening (HALT) or calcification was confirmed in all patients. "The initial clinical results of SIKELIA™ mark a significant milestone in our mission to transform patient care," said Peggy Wang, CEO of MitrAssist. "We are excited about the potential SIKELIA has to improve outcomes for patients suffering from severe aortic stenosis. SIKELIA capabilities and these initial results provide a foundation for the next phases of clinical testing, and we look forward to continuing our work to bring this innovation to physicians and patients around the world." The presentation at the TCT Conference attracted the attention of top physicians, industry leaders and medical professionals eager to explore more about the product. Dr. Xiaochun Zhang from Zhongshan Hospital and the Shanghai Medical College of Fudan University presented the initial results of this first-in-human, prospective, single-arm, multicenter study, on behalf of the study investigators. In addition to Zhongshan Hospital, the participating centers included Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Xiamen Cardiovascular Hospital Xiamen University and Zibo Central Hospital. "The initial outcomes we are seeing from SIKELIA™ could represent a real breakthrough in the TAVR field," said Prof. Junbo Ge from Zhongshan Hospital, principal investigator of the clinical trial. "The potential for improving patients' outcomes is immense, and we are eager to continue gathering data and enhancing the application of this technology. These results are just the beginning, and they pave the way for more comprehensive studies in the near future." For further information, please visit MITRASSIST LIFESCIENCES LIMITED is a leading global company for innovative cardiovascular medical devices, focusing on providing advanced diagnostic and therapeutic solutions for cardiovascular patients. The company product line covers a wide range of applications in the cardiovascular field from structural heart disease to heart failure. MitrAssist is dedicated and committed to innovation and improving patient care. Logo: SOURCE MitrAssist Lifesciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED